What is the Market Cap of Biocon?

It refers to the market value of the company's publicly traded shares. The market capitalization for Biocon is Rs 32644.31 billion as of 18 Apr, 2024.

Is Biocon a govt company?

Biocon is a non-government public company in India.

What is the promoter shareholding in Biocon?

On 31 December 2023, the promoter shareholding of the company was 60.64%.

Is Biocon profitable?

Biocon Ltd. generated a net profit of Rs 462.70 crore in 2023.

Who is the Managing Director of Biocon Limited?

Siddharth Mittal serves as the managing director of the company.

What is the ROE of Biocon Limited?

The company's ROE is quite fair at 9%. But it still needs to improve.

What is the debt-to-equity ratio of Biocon Limited?

The company's debt-to-equity ratio is 39%, suggesting a positive balance sheet.

What is the stock price CAGR of Biocon Limited?

The company's stock price CAGR is 24% for 10 years, 17% for 5 years, 5% for 3 years, and -21 % for 1 year.

How many times has Biocon Limited given dividends since 2004?

Since 2024, the company has given dividends four times.

Is it a good time to invest in Biocon Limited?

On a trailing 12-month basis, the operating revenue of the company stands at Rs 7290.70 crores. The annual revenue growth of 14% and a 16% pre-tax margin are also great. But the stock is getting mixed reviews.

Which are the key peers to Biocon?

The key peers of Biocon include Aarti Industries Ltd., Glenmark Pharmaceuticals Ltd., Gland Pharma Ltd., Piramal Pharma Ltd., and Syngene International Ltd.

How can I quickly analyze Biocon stock?

You can evaluate the Biocon stock by looking at metrics like the PE ratio, earning per share, price/sales ratio, and price-to-book ratio.

Who's the owner of Biocon?

Kiran Mazumdar Shaw owns Biocon. She is the founder and chairperson of the company.

What is the 52 Week High and Low of Biocon?

It is the highest and lowest price of Biocon over a period of 52 weeks. The 52 week high is Rs 307.10 and the low is Rs 191.55.

What is the PE and PB ratio of Biocon?

The PE ratio is 26.68, and the PB ratio is 1.46.

What is the Share Price of Biocon?

It will keep varying depending on countless factors. The share price of Biocon is Rs 0.00 as of 13 Feb 2024.

How to Buy Biocon Share?

Create your demat account on IIFL with proper KYC documents and undergo verification to buy the stock.

Biocon Ltd - BIOCON Share Price

Sector: Pharmaceuticals | ISIN: INE376G01013

₹ 271.90 (3.09%)

18 Apr, 2024, 9:07:07 AM

Trade

Expiry Date:

BIOCON - 25-04-2024

CALLS						PUTS
Total OI	Chg in Ol	Chg % Ol	LTP	Chg %	Strike Price	Chg %	LTP	Chg % OI	Chg in Ol	Total OI
7500	0	0.00	48	0.00	220.00	0.00	0.25	0.0	0	92500
5000	0	0.00	37.5	0.00	230.00	-50.00	0.2	-2.82	-5000	172500
-	-	-	-	0.00	232.50	0.00	0.4	0.0	0	10000
0	0	0.00	44.45	0.00	235.00	0.00	-	-	-	-
35000	0	0.00	25.4	0.00	240.00	-50.00	0.35	0.62	5000	807500
10000	0	0.00	21.15	0.00	245.00	-50.00	0.55	0.0	0	285000
157500	0	0.00	23.3	0.00	250.00	-57.14	0.75	-0.29	-2500	865000
52500	0	0.00	12	0.00	255.00	-59.32	1.2	-5.45	-22500	390000
2500	0	0.00	19.65	0.00	257.50	0.00	-	-	-	-
460000	-5000	-1.08	13.9	-1.08	260.00	-54.84	2.1	-0.57	-7500	1302500

Open
₹ 271.90

Prev. Close
₹ 263.75

Turnover(lac)
₹ 0.00

Day's High
₹ 271.90

Day's Low
₹ 271.90

52 Wk High
₹ 307.10

52 Wk Low
₹ 217.50

Book Value
₹ 91.79

Face Value
₹ 5.00

Mkt. Cap (Cr.)
₹ 32,644.31

P/E
0.00

EPS
0.40

Div. Yield
0.57

Biocon Ltd Corporate Actions

10 Jan , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

10 Jan , 2024

12:00 AM

Results

View Details

09 Oct , 2023

12:00 AM

Results

View Details

09 Oct , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

23 May , 2023

12:00 AM

AGM

Announcement date: 23 May , 2023

View Details

21 Jul , 2023

12:00 AM

Results

View Details

21 Jul , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

23 May , 2023

12:00 AM

Dividend

Dividend amount: 1.5
Announcement date: 23 May , 2023

View Details

20 Apr , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

20 Apr , 2023

12:00 AM

Results

View Details

23 Apr , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

No Record Found

Biocon Ltd News and Update

Biocon Biologics slips ~6% after CFO Indranil Sen steps down

Indranil Sen has resigned to seek possibilities outside of the organisation.

Eris Lifesciences purchases Biocon Biologics’ domestic brand formulations biz

As part of the agreement, around 430 people from the company are scheduled to migrate to Eris.

15 Mar, 2024 |
11:38 AM

Biocon soars on US market entry deal with J&J

Under the terms of the agreement, the product may be introduced in the US in February 2025 after receiving FDA approval.

01 Mar, 2024 |
11:31 AM

Biocon Faces ₹3 Crore Penalty Over GST-Related Issues, Plans Appeal

The penalty of ₹3,03,78,465 was imposed on February 22, 2024, by the Deputy Commissioner of Commercial Taxes, Divisional GST Office, Bangalor

26 Feb, 2024 |
4:20 PM

Biocon Ltd FINANCIALS

Select Period:

Particulars ( Rupees In Crores.)	--	--	--	--
Gross Sales	--	--	--	--
Excise Duty	--	--	--	--
Net Sales	--	--	--	--
Other Operating Income	--	--	--	--
Other Income	--	--	--	--
Total Income	--	--	--	--
Total Expenditure **	--	--	--	--
PBIDT	--	--	--	--
Interest	--	--	--	--
PBDT	--	--	--	--
Depreciation	--	--	--	--
Minority Interest Before NP	--	--	--	--
Tax	--	--	--	--
Deferred Tax	--	--	--	--
Reported Profit After Tax	--	--	--	--
Minority Interest After NP	--	--	--	--
Net Profit after Minority Interest	--	--	--	--
Extra-ordinary Items	--	--	--	--
Adjusted Profit After Extra-ordinary item	--	--	--	--
EPS (Unit Curr.)	--	--	--	--
Book Value (Unit Curr.)	--	--	--	--
Dividend (%)	--	--	--	--
Equity	--	--	--	--
Public Shareholding (Number)	--	--	--	--
Public Shareholding (%)	--	--	--	--
Pledged/Encumbered - No. of Shares	--	--	--	--
Pledged/Encumbered - % in Total Promoters Holding	--	--	--	--
Pledged/Encumbered - % in Total Equity	--	--	--	--
Non Encumbered - No. of Shares	--	--	--	--
Non Encumbered - % in Total Promoters Holding	--	--	--	--
Non Encumbered - % in Total Equity	--	--	--	--
PBIDTM(%)	--	--	--	--
PBDTM(%)	--	--	--	--
PATM(%)	--	--	--	--

No Record Found

Particulars ( Rupees In Crores.)	--	--	--	--
Gross Sales	--	--	--	--
Excise Duty	--	--	--	--
Net Sales	--	--	--	--
Other Operating Income	--	--	--	--
Other Income	--	--	--	--
Total Income	--	--	--	--
Total Expenditure **	--	--	--	--
PBIDT	--	--	--	--
Interest	--	--	--	--
PBDT	--	--	--	--
Depreciation	--	--	--	--
Minority Interest Before NP	--	--	--	--
Tax	--	--	--	--
Deferred Tax	--	--	--	--
Reported Profit After Tax	--	--	--	--
Minority Interest After NP	--	--	--	--
Net Profit after Minority Interest	--	--	--	--
Extra-ordinary Items	--	--	--	--
Adjusted Profit After Extra-ordinary item	--	--	--	--
EPS (Unit Curr.)	--	--	--	--
Book Value (Unit Curr.)	--	--	--	--
Dividend (%)	--	--	--	--
Equity	--	--	--	--
Public Shareholding (Number)	--	--	--	--
Public Shareholding (%)	--	--	--	--
Pledged/Encumbered - No. of Shares	--	--	--	--
Pledged/Encumbered - % in Total Promoters Holding	--	--	--	--
Pledged/Encumbered - % in Total Equity	--	--	--	--
Non Encumbered - No. of Shares	--	--	--	--
Non Encumbered - % in Total Promoters Holding	--	--	--	--
Non Encumbered - % in Total Equity	--	--	--	--
PBIDTM(%)	--	--	--	--
PBDTM(%)	--	--	--	--
PATM(%)	--	--	--	--

No Record Found

Biocon Ltd PEER COMPARISON

Company Name	LTP (₹)	P/E (%)	Mkt.Cap (₹Cr.)	NP Qtr (₹Cr.)	Div.Yield (%)	Sales Qtr (₹.Cr)	Book Value (₹)
Sun Pharmaceuticals Industries Ltd	1,536.65	89.51	3,68,765.79	721.31	0.75	4,903.66	100.23
Cipla Ltd	1,375.25	33.78	1,11,097.74	1,114.14	0.62	3,798.31	320.58
Dr Reddys Laboratories Ltd	6,084.50	25.37	1,00,958.41	475.20	0.66	4,083.10	1,361.85
Divis Laboratories Ltd	3,752.95	73.27	99,939.63	358.00	0.80	1,808.00	474.52
Zydus Lifesciences Ltd	945.95	35.39	95,104.21	450.40	0.64	2,225.10	145.11

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Biocon Ltd

Kiran Mazumdar Shaw
Chairperson

Ravi Mazumdar
Director

Vijay Kumar Kuchroo
Independent Director

M Damodaran
Independent Director

Bobby Parikh
Independent Director

Mayank Verma
Company Sec. & Compli. Officer

SIDDHARTH MITTAL
Managing Director & CEO

Eric Vivek Mazumdar
Director

Naina Lal Kidwai
Independent Director

Peter John Bains
Independent Director

Summary

Biocon Limited is Indias largest and fully-integrated, innovation-led biopharmaceutical company. The Company is engaged in the manufacture of biotechnology products and research services. Biocon Limited was incorporated in the year 1978 as a joint venture between Biocon Biochemicals Limited of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw. Biocon manufactured and exported enzymes to USA and Europe during the year 1979, as first of its kind. In 1989, Unilever plc acquired the Biocon Biochemicals Limited in Ireland and merges it with its subsidiary, Quest International. Also in the same year, the company had received US funding for proprietary technologies. After a year, in 1990, Biocon had scaled up its in-house research programme, based on a proprietary solid substrate fermentation technology, from pilot to plant level. Biocons R&D and manufacturing facilities received ISO 9001 certification from RWTUV, Germany during the period of 1993. In the year 1994, the company had established the Syngene International Pvt. Ltd. as a Custom research Company (CRC) to address the growing need for outsourced R&D in the pharmaceutical sector. The commercial success of Biocons proprietary fermentation plant leads to a 3-fold expansion during the year 1996 and also in the same year, the company had leveraged its technology platform to enter biopharmaceuticals and statins. Biocon had spearheads initiatives in human healthcare in the year 1997 through a dedicated manufacturing... Read More

Reports by Biocon Ltd
Annual ReportAuditors Report
Management DiscussionDirectors Report

Reports by Biocon Ltd
Investor PresentationConference Call TranscriptConference Call Audio

Company FAQ

What is the Market Cap of Biocon?
It refers to the market value of the company's publicly traded shares. The market capitalization for Biocon is Rs 32644.31 billion as of 18 Apr, 2024.
Is Biocon a govt company?
Biocon is a non-government public company in India.
What is the promoter shareholding in Biocon?
On 31 December 2023, the promoter shareholding of the company was 60.64%.
Is Biocon profitable?
Biocon Ltd. generated a net profit of Rs 462.70 crore in 2023.
Who is the Managing Director of Biocon Limited?
Siddharth Mittal serves as the managing director of the company.
What is the ROE of Biocon Limited?
The company's ROE is quite fair at 9%. But it still needs to improve.
What is the debt-to-equity ratio of Biocon Limited?
The company's debt-to-equity ratio is 39%, suggesting a positive balance sheet.
What is the stock price CAGR of Biocon Limited?
The company's stock price CAGR is 24% for 10 years, 17% for 5 years, 5% for 3 years, and -21 % for 1 year.
How many times has Biocon Limited given dividends since 2004?
Since 2024, the company has given dividends four times.
Is it a good time to invest in Biocon Limited?
On a trailing 12-month basis, the operating revenue of the company stands at Rs 7290.70 crores. The annual revenue growth of 14% and a 16% pre-tax margin are also great. But the stock is getting mixed reviews.
What is the PB ratio of Biocon?
The PB ratio of Biocon is 1.4.
Which are the key peers to Biocon?
The key peers of Biocon include Aarti Industries Ltd., Glenmark Pharmaceuticals Ltd., Gland Pharma Ltd., Piramal Pharma Ltd., and Syngene International Ltd.
How can I quickly analyze Biocon stock?
You can evaluate the Biocon stock by looking at metrics like the PE ratio, earning per share, price/sales ratio, and price-to-book ratio.
Who's the owner of Biocon?
Kiran Mazumdar Shaw owns Biocon. She is the founder and chairperson of the company.
What is the 52 Week High and Low of Biocon?
It is the highest and lowest price of Biocon over a period of 52 weeks. The 52 week high is Rs 307.10 and the low is Rs 191.55.
What is the PE and PB ratio of Biocon?
The PE ratio is 26.68, and the PB ratio is 1.46.
What is the Share Price of Biocon?
It will keep varying depending on countless factors. The share price of Biocon is Rs 0.00 as of 13 Feb 2024.
How to Buy Biocon Share?
Create your demat account on IIFL with proper KYC documents and undergo verification to buy the stock.

ATTENTION INVESTORS

Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

Risk Disclosure on Derivatives

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to Rs. 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

We are ISO 27001:2013 Certified.

This certificate demonstrates that IIFL as an organization has defined and put in place best-practice information security processes.

ATTENTION INVESTORS

Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

Risk Disclosure on Derivatives

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to Rs. 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

We are ISO 27001:2013 Certified.

This certificate demonstrates that IIFL as an organization has defined and put in place best-practice information security processes.